Relationship between transfusion regimen and suppression of erythropoiesis in β‐thalassaemia major
- 1 March 1995
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 89 (3) , 473-478
- https://doi.org/10.1111/j.1365-2141.1995.tb08351.x
Abstract
In the management of β-thalassaemia major, different transfusion schemes are employed with baseline haemoglobin levels ranging from 8 to over 12 g/dl. We studied the relationship between transfusion regimen and suppression of erythropoiesis in 52 patients with β-thalassaemia major whose mean pretransfusion haemoglobin levels ranged from 8.6 to 10.9 g/dl. Multiple, regression analysis showed that serum transferrin receptor was the parameter more closely related to mean pretransfusion haemoglobin (r = -0.77, P < 0.001). As measured through serum transferrin receptor, erythroid activity was 1-2 times normal for pretransfusion haemoglobin levels between 10 and 11 g/dl, 1-4 times normal for levels from 9 to 10 g/dl, and 2-6 times normal for levels from 8.6 to 9 g/dl. Mean pretransfusion haemoglobin was also inversely related to serum erythropoietin (r = -0.72, P < 0.001), whereas it showed no or a weak relationship with Hb F, reticulocyte count, or circulating nucleated red cell count. This study suggests that serum transferrin receptor is a reliable indicator of suppression of erythropoiesis in β-thalassaemia major. On the basis of our findings, pretransfusion haemoglobin values of ≦ 9 g/dl should be adopted with caution, because these levels can be associated with an insufficient inhibition of erythroid marrow expansion. However, a transfusion programme, with a baseline haemoglobin of 9-10 g/dl, may provide enough suppression of erythropoiesis and allow a reduction in blood consumption as compared with the classic hyper- or supertransfusion schemes. Since fixed haemoglobin levels may not be the best target for transfusion treatment in all thalassaemic patients, assay of serum transferrin receptor may be helpful for individualizing the transfusion regimens.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Soluble transferrin receptor in beta-thalassaemiaThe Lancet, 1993
- Serum erythropoietin levels in thalassemia intermediaAnnals of Hematology, 1993
- The clinical significance of serum transferrin receptor levels in sickle cell diseaseBritish Journal of Haematology, 1993
- Bone Marrow Transplantation in Patients with ThalassemiaNew England Journal of Medicine, 1990
- Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemiasBritish Journal of Haematology, 1983
- Relation between Erythropoiesis and Bone Metabolism in ThalassemiaNew England Journal of Medicine, 1981
- IRON LOADING IN β-THALASSÆMIAThe Lancet, 1980
- Erythropoiesis and the Effect of Transfusion in Homozygous β-ThalassemiaNew England Journal of Medicine, 1978
- IRON ABSORPTION IN IRON-LOADING ANÆMIAS: EFFECT OF SUBCUTANEOUS DESFERRIOXAMINE INFUSIONSThe Lancet, 1977